Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Firefly Metals reports 11.5 m at 13.2% copper equivalent at Green Bay project in Canada

Firefly Metals reports 11.5 m at 13.2% copper equivalent at Green Bay project in Canada

ReutersReuters2026/08/03 01:53
  • Firefly Metals reported new high-grade drill assays at its Green Bay copper-gold project in Newfoundland and Labrador, targeting a near-term resource update.
  • Upper VMS zones returned intercepts including 11.5 m at 13.2% CuEq, 18.9 m at 8.2% CuEq, 13.5 m at 11.1% CuEq.
  • Core Zone drilling hit 65.3 m at 4.3% CuEq, supporting plans to lift Measured and Indicated resources for restart studies.
  • Preliminary Economic Assessment remains on track for completion by end-August 2026; mine plan targets at least 70% Measured and Indicated material.
  • Green Bay resource stands at 50.4 Mt at 2% CuEq Measured and Indicated, 29.3 Mt at 2.5% CuEq Inferred; cash and liquid investments A$ 196.4 million at June 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Firefly Metals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608022152PRIMZONEFULLFEED9802285) on August 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma